CELEX ONCOLOGY INNOVATIONS LIMITED

CELEX ONCOLOGY INNOVATIONS LIMITED

  • Overview
  • Summary
  • Purpose
  • Address
  • Accounts
  • Confirmation Statement
  • Filings
  • Officers
  • Persons with significant controls
  • Persons with signficant control statements
  • Data Source
  • Overview

    Company NameCELEX ONCOLOGY INNOVATIONS LIMITED
    Company StatusActive
    Legal FormPrivate limited company
    Company Number 11085607
    JurisdictionEngland/Wales
    Date of Creation

    Summary

    Has Super Secure PSCsNo
    Has ChargesNo
    Has Insolvency HistoryNo
    Registered Office is in DisputeNo

    What is the purpose of CELEX ONCOLOGY INNOVATIONS LIMITED?

    • Manufacture of basic pharmaceutical products (21100) / Manufacturing

    Where is CELEX ONCOLOGY INNOVATIONS LIMITED located?

    Registered Office Address
    101 New Cavendish Street
    1st Floor South
    W1W 6XH London
    United Kingdom
    Undeliverable Registered Office AddressNo

    What are the latest accounts for CELEX ONCOLOGY INNOVATIONS LIMITED?

    OverdueNo
    Next Accounts
    Next Accounts Period End OnDec 31, 2025
    Next Accounts Due OnSep 30, 2026
    Last Accounts
    Last Accounts Made Up ToDec 31, 2024

    What is the status of the latest confirmation statement for CELEX ONCOLOGY INNOVATIONS LIMITED?

    Last Confirmation Statement Made Up ToApr 05, 2026
    Next Confirmation Statement DueApr 19, 2026
    Last Confirmation Statement
    Next Confirmation Statement Made Up ToApr 05, 2025
    OverdueNo

    What are the latest filings for CELEX ONCOLOGY INNOVATIONS LIMITED?

    Filings
    DateDescriptionDocumentType

    Total exemption full accounts made up to Dec 31, 2024

    9 pagesAA

    Registration of charge 110856070001, created on Nov 17, 2025

    64 pagesMR01

    Termination of appointment of Rached Sami Bakri as a director on Sep 26, 2025

    1 pagesTM01

    Confirmation statement made on Apr 05, 2025 with updates

    7 pagesCS01

    Notification of a person with significant control statement

    2 pagesPSC08

    Cessation of Mustafa Bilgin Ali Djamgoz as a person with significant control on Nov 21, 2024

    1 pagesPSC07

    Change of details for Professor Mustafa Bilgin Ali Djamgoz as a person with significant control on Feb 14, 2024

    2 pagesPSC04

    Second filing of a statement of capital following an allotment of shares on Mar 24, 2024

    • Capital: GBP 829.5883
    7 pagesRP04SH01

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    legacy

    pagesANNOTATION

    Statement of capital following an allotment of shares on Dec 30, 2024

    • Capital: GBP 1,021.1821
    4 pagesSH01

    Second filing of a statement of capital following an allotment of shares on Mar 24, 2024

    • Capital: GBP 840.3183
    6 pagesRP04SH01

    Sub-division of shares on Aug 15, 2022

    6 pagesSH02
    Annotations
    DateAnnotation
    Jan 08, 2025Clarification This is a second filing of an SH02 that was originally registered on 13/09/2022

    Second filing of Confirmation Statement dated Dec 04, 2023

    5 pagesRP04CS01

    Second filing of Confirmation Statement dated Dec 04, 2022

    5 pagesRP04CS01

    Second filing of Confirmation Statement dated Dec 04, 2020

    5 pagesRP04CS01

    Second filing of Confirmation Statement dated Dec 04, 2019

    5 pagesRP04CS01

    Second filing of Confirmation Statement dated Apr 05, 2024

    7 pagesRP04CS01

    Second filing of a statement of capital following an allotment of shares on Mar 24, 2024

    • Capital: GBP 837.6358
    6 pagesRP04SH01

    Who are the officers of CELEX ONCOLOGY INNOVATIONS LIMITED?

    Officers
    NameAppointed OnResigned OnRoleAddressCompany IdentificationCountry of ResidenceNationalityDate of BirthOccupationNumber
    COHEN, Laurence John
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    Director
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    EnglandBritish195986490003
    FALTUM, Carsten Kronsbjerg
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    Director
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    SwitzerlandDanish260780260001
    HARIMOHAN, Bhavani, Dr
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    Director
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    United StatesAmerican326564110001
    BAKRI, Rached Sami, Dr
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    Director
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    EnglandBritish218664380002
    DJAMGOZ, Mustafa Bilgin Ali, Prof
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Director
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    United KingdomBritish79471220002
    MILLARD, Brian Percival De Thorpe
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Director
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    EnglandBritish262819130001
    RAHMAN, Ajmal
    New Cavendish Street
    W1G 8TB London
    64
    England
    Director
    New Cavendish Street
    W1G 8TB London
    64
    England
    EnglandBritish185656890001
    XENIADIS, Vasileios, Dr.
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Director
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    GreeceGreek262819180001

    Who are the persons with significant control of CELEX ONCOLOGY INNOVATIONS LIMITED?

    Persons with significant controls
    NameNotified OnAddressCeased
    Dr Vasileios Xeniades
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Sep 25, 2019
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Yes
    Nationality: Greek
    Country of Residence: Greece
    Natures of Control
    • The person has the right to exercise, or actually exercises, significant influence or control over the company.
    Professor Mustafa Bilgin Ali Djamgoz
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    Nov 28, 2017
    New Cavendish Street
    1st Floor South
    W1W 6XH London
    101
    United Kingdom
    Yes
    Nationality: British
    Country of Residence: United Kingdom
    Natures of Control
    • The person holds, directly or indirectly, more than 25% but not more than 50% of the shares in the company.
    • The person holds, directly or indirectly, more than 25% but not more than 50% of the voting rights in the company.
    Mr Laurence John Cohen
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Nov 28, 2017
    Pier Head
    L3 1JH Liverpool
    9th Floor, The Royal Liver Building
    United Kingdom
    Yes
    Nationality: United Kingdom
    Country of Residence: United Kingdom
    Natures of Control
    • The person holds, directly or indirectly, more than 25% but not more than 50% of the shares in the company.
    • The person holds, directly or indirectly, more than 25% but not more than 50% of the voting rights in the company.

    What are the latest statements on persons with significant control for CELEX ONCOLOGY INNOVATIONS LIMITED?

    Persons with signficant control statements
    Notified OnCeased OnStatement
    Nov 21, 2024The company knows or has reasonable cause to believe that there is no registrable person or registrable relevant legal entity in relation to the company

    Data Source

    • UK Companies House
      The official register of companies in the UK, providing public access to company information such as names, addresses, directors, and financial filings.
    • license: CC0